Minnesota Glomerular Disease Program
Front Row from Left to Right: Lama Ghazi, Michelle Hintz, Surabhi Thakar, Charlotte Quinton
Back Row from Left to Right: Rana Leed, Patrick Nachman, Katti Woerner, and Elizabeth Miller
Mission
To provide patients with glomerular disease with expert, individualized care and access to clinical trials.
Covered Diseases
- Any glomerular disease, including (but not limited to):
- Focal Segmental Glomerulosclerosis (FSGS)
- Membranous nephropathy
- Minimal change disease
- IgA nephropathy
- Immune complex mediated diseases
- C3 Glomerulopathy
- Fibrillary Glomerular Disease
- Cryoglobulinemia
- Anti-Glomerular Basement Membrane (anti-GBM) Disease
- Alport Syndrome
- Thin basement membrane disease
- Vasculitis
- Lupus Nephritis
- For systemic diseases associated with Systemic Lupus Erythematosus or vasculitis, please visit the Minnesota Multidisciplinary Vasculitis Program webpage
Goals
- Provide patients with glomerular disease with expert care which is organized, streamlined and efficient.
- Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
- Provide patients with access to cutting-edge clinical trials.
- Facilitate translational research.
- Provide a venue for health care providers training in the care of patients with glomerular disease.
Our Team
Physicians
Clinical & Translational Research Team
- Elizabeth Miller, RN, BAN, PHN, CCRC - Study Coordinator
- Mary McDonald, RN, CCRP - Study Coordinator
- Scott Rajala, CCRP - Translational Research Assistant
- Ghislaine Feussom - Study Coordinator
Ongoing Clinical Trials
MEMBRANOUS NEPHROPATHY
Phase 2 Trial
Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)
Principal Investigator
Study Coordinators
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Phase 3 Trial
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Principal Investigator
Michelle Rheault, MD
Study Coordinators
Amy Hanson, CCRC
amhanson@umn.edu
IGA NEPHROPATHY
Phase 3 Trial
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)
Principal Investigator
Surabhi Thakar, MD
Co-Investigator
Katti Woerner, MD
Study Coordinators
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Phase 3 Trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
Principal Investigator
Patrick H. Nachman, MD
Study Coordinators
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
Mary McDonald, RN, CCRP
mcdo0664@umn.edu